Karel C. Smit

Karel C. Smit

Auto-generated profile, based on publicly available information

Karel C. Smit

Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
RVRik J Verheijden
Rik J Verheijden
ABAnna Cabané Ballester
Anna Cabané Ballester
KSKarel C Smit
Karel C Smit
MEMick J M van Eijs
Mick J M van Eijs
CBCheryl P Bruijnen
Cheryl P Bruijnen
AMAnne M. May
Anne M. May
Background: Although animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the effects of PA on immune checkpoint inhibitor (ICI) toxicity and effectiveness in humans. We assessed the association of PA with immune-related adverse events (irAE) and survival in patients undergoing ICI. Methods: Patients receiving ICI who completed the Dutch short questionnaire to assess health enhancing physical activity (SQUASH) questionnaire at the start of treatment as part of the prospective UNICIT study in an academic hospital were included. PA was quantified by calculating total metabolic equivalent task hours per week (total PA) and hours per week of moderate- to vigorous-intensity PA during sport and leisure time (MVPA-SL). Associations of PA with severe irAE occurrence within 1 year and overall survival (OS) were evaluated using logistic regression and Cox proportional hazard regression, respectively, with adjustment for probable confounders. Results: In total, 251 patients were included, with a median follow-up of 20 months. Moderate and high levels of total PA were associated with lower odds of severe irAE occurrence compared to low levels of total PA (adjusted OR: 0.34 [95% CI = 0.12 to 0.90] and 0.19 [95% CI = 0.05 to 0.55], respectively). Moderate and high levels of total PA were also associated with prolonged survival (adjusted HR: 0.58 [95% CI = 0.32 to 1.04] and 0.48 [95% CI = 0.27 to 0.89], respectively). Similar associations were observed in patients who performed more MVPA-SL. Conclusions: Higher physical activity levels at the start of ICI treatment are associated with lower risk of severe irAEs and probably prolonged survival. Randomized controlled trials are needed to investigate whether patients indeed benefit from increasing PA levels after diagnosis.

10 March 2022 in European Journal of Cancer
Verified
Journal Article
Open access
JDJeroen W.G. Derksen
Jeroen W.G. Derksen
KSKarel C. Smit
Karel C. Smit
AMAnne M. May
Anne M. May
CPCornelis J.A. Punt
Cornelis J.A. Punt
S-1 is an oral fluoropyrimidine that is increasingly used in Western countries for the treatment of metastatic colorectal cancer (mCRC). We conducted a non-inferiority meta-analysis on the efficacy of S-1-based therapy versus 5-fluorouracil (5-FU)- or capecitabine-based therapy in the treatment of patients with mCRC. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Opengrey were searched for randomised clinical trials until May 2021. Data were extracted for progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and adverse events. Pooled effect estimates, stratified by treatment line, with corresponding 99% confidence intervals (CI) were presented. For PFS, a pre-defined non-inferiority margin (ΔNI) of 1.25 was selected. Ten studies (n = 2117) were included, of which six studies reported PFS and OS data and 10 studies reported ORR data. S-1-based therapy was shown to be non-inferior to 5-FU/capecitabine-based therapy in terms of PFS (HRtotal 0.95, 99% CI 0.83-1.08) with its CI upper limit well below ΔNI, and at least as efficacious in terms of OS (HRtotal 0.93, 99% CI 0.81-1.07), and ORR (RRtotal 1.06, 99% CI 0.90-1.24). S-1-based therapy is non-inferior to 5-FU/capecitabine-based therapy in the treatment of mCRC regarding PFS and at least as efficacious as 5-FU/capecitabine-based therapy in terms of ORR and OS. These data support the use of S-1 in mCRC patients who are intolerant to 5-FU/capecitabine-based treatment.

10 December 2024 in Cancer Epidemiology
Verified
Journal Article
Open access
JDJeroen W.G. Derksen
Jeroen W.G. Derksen
KSKarel C. Smit
Karel C. Smit
IHIrene W.F. Hoeven
Irene W.F. Hoeven
FSFemke P.C. Sijtsma
Femke P.C. Sijtsma
MKMiriam Koopman
Miriam Koopman
AMAnne M. May
Anne M. May
The nationwide Dietary Intake After Diagnosis and Colorectal Cancer Outcomes (PROTECT) study is a prospective cohort study investigating how lifestyle-related factors including dietary intake and physical activity are associated with health-related quality of life (HRQoL), recurrence, and survival after a colorectal cancer (CRC) diagnosis. Patients participating in the Prospective Dutch Colorectal Cancer (PLCRC) cohort with newly diagnosed stage I to IV colorectal cancer were recruited for PROTECT shortly after diagnosis, between 2015 and 2022. While patient-reported quality of life, physical activity, and sedentary behavior, as well as body composition data are available from PLCRC, patient-reported measurements in PROTECT included anthropometrics, dietary intake, dietary supplement use, and taste and smell alterations. Clinical data was obtained from the Netherlands Cancer Registry. Patients returned baseline questionnaires after a median of 43 days (IQR: 28-59) after diagnosis. At diagnosis, the 974 participants' median age was 65 years (IQR: 58, 72), 59 % were male, 59 % had overweight/obesity, and 28 % stage I, 25 % stage II, 40 % stage III, and 6 % stage IV disease. Dietary supplements more frequently used were multivitamins (35 %), vitamin D (30 %), vitamin C (15 %), and magnesium (14 %). Around diagnosis, changes in taste ability were reported by 6 % of patients, while 2 % experienced changes in smell, and 16 % reported experiencing a dry mouthfeel. In total, 24 % adhered to ESPEN dietary guideline of ≥ 25 kCal/kg/day plus ≥ 1 gram protein/kg/day, while 45 % adhered to international physical activity guidelines. PROTECT is a unique nationwide cohort of CRC patients with a wealth of lifestyle-related data obtained through patient-reported measurements, of which baseline assessments were presented. PROTECT participants will be followed until deceased or lost to follow-up to collect all clinical outcome data. PROTECT will inform clinical and public health guidelines on physical activity and dietary patterns for improving CRC outcomes and survivorship.

3 May 2024 in International Journal of Cancer
Verified
Journal Article
Open access
ALAnne‐Sophie van Lanen
Anne‐Sophie van Lanen
DKDieuwertje Kok
Dieuwertje Kok
EWEvertine Wesselink
Evertine Wesselink
JDJeroen W. G. Derksen
Jeroen W. G. Derksen
AMAnne M. May
Anne M. May
TSThe Colon And Plcrc Studies
The Colon And Plcrc Studies
We previously demonstrated that intake of low‐fat dairy, but not high‐fat dairy, was associated with a decreased colorectal cancer (CRC) recurrence risk. These risks, however, may differ by sex, primary tumour location, and disease stage. Combining data from two similar prospective cohort studies of people with stage I–III CRC enabled these subgroup analyses. Participants completed a food frequency questionnaire at diagnosis (n = 2283). We examined associations between low‐ and high‐fat dairy intake and recurrence risk using multivariable Cox proportional hazard models, stratified by sex, and primary tumour location (colon and rectum), and disease stage (I/II and III). Upper quartiles were compared to lower quartiles of intake, and recurrence was defined as a locoregional recurrence and/or metastasis. During a median follow‐up of 5.0 years, 331 recurrences were detected. A higher intake of low‐fat dairy was associated with a reduced risk of recurrence (hazard ratio [HR]: 0.60, 95% confidence interval [CI]: 0.43–0.83), which seemed more pronounced in men (HR: 0.51, 95% CI: 0.34–0.77) than in women (HR: 0.84, 95% CI: 0.47–1.49). A higher intake of high‐fat dairy was associated with an increased risk of recurrence in participants with colon cancer (HR: 1.60, 95% CI: 1.03–2.50), but not rectal cancer (HR: 0.88, 95% CI: 0.54–1.45). No differences in associations were observed between strata of disease stage. Concluding, our findings imply that dietary advice regarding low‐fat dairy intake may be especially important for men with CRC, and that dietary advice regarding high‐fat dairy intake may be specifically important in people with colon cancer.

3 December 2021 in Biological Psychiatry
Verified
Journal Article
Closed access
PDF file
EBElemi J. Breetvelt
Elemi J. Breetvelt
KSKarel C. Smit
Karel C. Smit
JSJessica van Setten
Jessica van Setten
DMDaniele Merico
Daniele Merico
XWXiao Wang
Xiao Wang
JVJacob A.S. Vorstman
Jacob A.S. Vorstman

10 July 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
KSKarel C. Smit
Karel C. Smit
JDJeroen W.G. Derksen
Jeroen W.G. Derksen
SKSophie A. Kurk
Sophie A. Kurk
PMPim Moeskops
Pim Moeskops
MKMiriam Koopman
Miriam Koopman
AMAnne M. May
Anne M. May
Background: Low muscle mass and skeletal muscle mass (SMM) loss are associated with adverse patient outcomes, but the time-consuming nature of manual SMM quantification prohibits implementation of this metric in clinical practice. Therefore, we assessed the feasibility of automated SMM quantification compared to manual quantification. We evaluated both diagnostic accuracy for low muscle mass and associations of SMM (change) with survival in colorectal cancer (CRC) patients. Methods: Computed tomography (CT) images from CRC patients enrolled in two clinical studies were analyzed. We compared i) manual vs. automated segmentation of preselected slices at the third lumbar [L3] vertebra ("semi-automated"), and ii) manual L3-slice-selection + manual segmentation vs. automated L3-slice-selection + automated segmentation ("fully-automated"). Automated L3-selection and automated segmentation was performed with Quantib Body Composition v0.2.1. Bland-Altman analyses, within-subject coefficients of variation (WSCVs) and Intraclass Correlation Coefficients (ICCs) were used to evaluate the agreement between manual and automatic segmentation. Diagnostic accuracy for low muscle mass (defined by an established sarcopenia cut-off) was calculated with manual assessment as the "gold standard". Using either manual or automated assessment, Cox proportional hazard ratios (HRs) were used to study the association between changes in SMM (>5% decrease yes/no) during first-line metastatic CRC treatment and mortality adjusted for prognostic factors. SMM change was also assessed separately in weight-stable (<5%, i.e. occult SMM loss) patients. Results: In total, 1580 CT scans were analyzed, while a subset of 307 scans were analyzed in the fully-automated comparison. Included patients (n = 553) had a mean age of 63 +/- 9 years and 39% were female. The semi-automated comparison revealed a bias of -2.41 cm(2), 95% limits of agreement [-9.02 to 4.20], a WSCV of 2.25%, and an ICC of 0.99 (95% confidence intervals (CI) 0.97 to 1.00). The fully-automated comparison method revealed a bias of -0.08 cm(2) [-10.91 to 10.75], a WSCV of 2.85% and an ICC of 0.98 (95% CI 0.98 to 0.99). Sensitivity and specificity for low muscle mass were 0.99 and 0.89 for the semi-automated comparison and 0.96 and 0.90 for the fully-automated comparison. SMM decrease was associated with shorter survival in both manual and automated assessment (n = 78/280, HR 1.36 [95% CI 1.03 to 1.80] and n = 89/280, HR 1.38 [95% CI 1.05 to 1.81]). Occult SMM loss was associated with shorter survival in manual assessment, but not significantly in automated assessment (n = 44/263, HR 1.43 [95% CI 1.01 to 2.03] and n = 51/2639, HR 1.23 [95% CI 0.87 to 1.74]). Conclusion: Deep-learning based assessment of SMM at L3 shows reliable performance, enabling the use of CT measures to guide clinical decision making. Implementation in clinical practice helps to identify patients with low muscle mass or (occult) SMM loss who may benefit from lifestyle interventions. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism. This is an open access article under the CC BY license (http://creativecommons.org/licenses/